Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

Completed

Conditions studied: Cancer

In brief

This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.

Key facts

Study ID

NCT07636863

Run by

Bristol-Myers Squibb

People needed

200

Starts

2025-08-21

Expected to finish

2026-03-27

Last updated by the study team

2026-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are ≥ 18 years of age at the index date
• Have a confirmed cancer diagnosis
• Received one of the following treatments:
• Intravenous (IV) nivolumab
• Subcutaneous (SC) nivolumab + hyaluronidase

You may not qualify if…

• Currently receiving a clinical trial therapy at index
• Currently receiving treatment for another active concurrent primary cancer diagnosis
• Received IV nivolumab or SC nivolumab + hyaluronidase off-label

Where it is running

• Florida Cancer Specialists & Research Institute — Fort Myers, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.